SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today announced that it has launched Cefepime Hydrochloride for Injection, the generic equivalent of Maxipime® marketed by Elan Corporation, plc. APP’s cefepime is AP-rated, bar-coded and latex-free. According to IMS data, sales of Cefepime Hydrochloride in the United States were approximately $173 million in 2007.
